SARASOTA, FL (PRWEB) October 08, 2012
Rapid Pathogen Screening, Inc. (RPS®), an emerging leader in point-of-care (POC) diagnostic testing, today announced that Caroline Popper, MD, MPH, and Hanjoon Ryu have been appointed as independent members of its Board of Directors. The extensive POC industry experience, knowledge, and contacts that Popper and Ryu bring expands the breadth and capabilities of the RPS Board to help guide the company’s strategic growth.
Throughout her 21-year career, Caroline Popper held senior leadership positions at corporations such as Becton Dickinson & Company and MDS Proteomics, Inc. In 2003, Popper co-founded an advisory consulting firm of which she has since served as founder and president. Popper’s strengths include creating and implementing regulatory strategies, evaluating competitive technology and product development opportunities, and influencing commercial plans and partnerships. Popper earned her Doctor of Medicine (MD) degree from the University of the Witwatersrand in South Africa and her Master of Public Health (MPH) degree from Johns Hopkins University (JHU). She completed her residencies in internal medicine and pathology at JHU.
Hanjoon Ryu established himself as a POC expert during his 21-year career in clinical diagnostics. He held senior leadership positions with Dade Behring, Inc. and Siemens Healthcare Diagnostics. For three years, Ryu successfully led Siemens’ POC business with responsibility for strategy, business development, global marketing, and new product development. Ryu’s experience will significantly enhance RPS’s global market understanding and strategic initiatives. Ryu earned his Master in Business Administration (MBA) degree from The University of Pennsylvania’s Wharton School and his Master’s degree in Marketing and Bachelor’s degree in Business Administration from Yonsei University in South Korea.
“I am excited about the invaluable global POC diagnostic experience and expertise that Caroline and Hanjoon bring to our team,” said Robert Sambursky, MD, Chief Executive Officer, President, and Chairman of RPS. “Their active involvement will be instrumental in helping RPS continue to build its commercial momentum to become a worldwide leader in POC diagnostics.”
Founded in 2004, Rapid Pathogen Screening, Inc. (RPS®) is an emerging developer, manufacturer, and marketer of rapid point-of-care (POC) diagnostic tests. The company’s innovative and patented technology platform facilitates the development of a spectrum of cost-effective tests to rapidly identify patients with infectious diseases and inflammatory conditions. As a result of U.S. government contracts, this platform is also being used to develop tests for bio-terrorism and chemical nerve agent blood toxins. RPS tests have high sensitivity and specificity, and can be easily performed by a clinician or their staff without extensive training or additional equipment. For more information on RPS or its products, visit RPSdetectors.com.
# # #
For additional information, contact:
Laura Lovejoy, Director of Strategic Marketing, RPS, 941.556.1864, lovejoy(at)rpsdetectors(dot)com